Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Camrelizumab for Chinese NSCLC Patients: a Prospective, Observational, Multicenter Real-World Study
Conditions
Interventions
Camrelizumab
Start Date
April 1, 2021
Primary Completion Date
June 30, 2024
Completion Date
December 30, 2024
Last Updated
March 11, 2021
NCT07190248
NCT06305754
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Guangdong Association of Clinical Trials
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions